Author

M. A. Barry

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1 Assay:protein sequence· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Parrett· 2 shared J. Rubin· 2 shared A. Drelich· 1 shared A. G. Basnakian· 1 shared A. T. Baker· 1 shared B. Jacobs· 1 shared B. M. Nagalo· 1 shared C. C. Simoes· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

B. Parrett

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers

B. M. Nagalo, Y. Zhou, E. L. Loeuillard, C. Dumbauld, O. Barro, N. Elliott, A. T. Baker, M. Arora, J. M. Bogenberger, N. Meurice, J. Petit, P. L. S. Uson Junior, F. Aslam, J. C. Chamcheu, C. C. Simoes, , M. Borad

This study characterizes Morreton virus (MORV) as a safe and effective oncolytic virotherapy for liver cancers, showing tumor regression in animal models with lower doses than VSV.

Hepatology · Jun 1, 2023Peer-reviewedImmunology

Ex Vivo and In Vivo CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26)

J. R. Hemsath, M. Liaci, J. Rubin, B. Parrett, S.-C. Lu, T. Nguyen, M. Turner, C. Chen, V. S. Reddy, K. Cupelli, T. Stehle, K. Liszewski, J. Atkinson, M. A. Barry

This paper investigates the CD46 receptor utilization by Ad26 in vitro and in vivo, showing its role in infection and safety, but not all routes of administration.

Journal of Virology · Feb 9, 2022Peer-reviewedPharmacology & Toxicology

Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines

M. A. Barry, H. Mudrick, E. McGlinch, B. Parrett, J. Hemsath, M. Barry, J. Rubin, C. Uzendu, M. Hansen, C. Erskine, V. VanKeulen, A. Drelich, C.-T. K. Tseng, C. S. Massey, M. Fida, , G. Olivier

This study compares mucosal and intramuscular immunization with replication-defective and replicating single-cycle adenovirus vaccines against SARS-CoV-2, showing that replicating vaccines generate stronger antibody responses.

bioRxiv · Apr 20, 2021 · PreprintImmunology